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Abstract: We are entering an era where the efficacy of current antibiotics is declining, due 
to the development and widespread dispersion of antibiotic resistance mechanisms.  
These factors highlight the need for novel antimicrobial discovery. A large number of 
antimicrobial natural products elicit their effect by directly targeting discrete areas of 
peptidoglycan metabolism. Many such natural products bind directly to the essential cell 
wall precursor Lipid II and its metabolites, i.e., preventing the utlisation of vital substrates 
by direct binding rather than inhibiting the metabolising enzymes themselves. Concurrently, 
there has been an increase in the knowledge surrounding the proteins essential to the 
metabolism of Lipid II at and across the cytoplasmic membrane. In this review, we draw 
these elements together and look to future antimicrobial opportunities in this area. 
Keywords: peptidoglycan; Lipid I; Lipid II; MraY; MurG; Lipid II flippase; FtsW; MurJ; 
undecaprenyl pyrophosphate phosphatases 
 
1. Introduction 
Antimicrobial resistance undermines healthcare on an enormous scale with an associated societal and 
economic impact that is finally starting to influence policy at a governmental level, prompting  
the re-engagement of the pharmaceutical industry in this area [1–3]. The focus of much attention at the 
research level has been on the search for novel or reconsidered aspects of bacterial metabolism to target 
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and on the search for drug candidates with the required properties to be a success in the clinic, addressing 
issues of resistance. There is a growing appreciation that antibiotics that multi-target cellular activities, 
such as β-lactam inhibition of penicillin binding proteins (PBPs) in the same organism responsible for 
peptidoglycan biosynthesis, present the most successful opportunities for antibacterial therapeutics [4]. 
However, β-lactam treatment itself can be subject to resistance through a number of different routes 
including inactivation of the β-lactam chemical core by corresponding lactamase enzymes or efflux by 
outer membrane pumps, as seen in many Gram-negative bacterial pathogens. In addition, β-lactam 
resistance can be achieved by alternative peptidoglycan stem peptide crosslinking chemistry,  
utilising 3-3 L,D-transpeptidase enzymes (compared to the PBPs above which are generally considered 
to be responsible for the formation of 3-4 crosslinks between stem peptides, Figure 1) that are  
unaffected by β-lactam [5,6], the acquisition of β-lactam-insensitive transpeptidase PBPs as seen in  
methicillin-resistant Staphylococcus aureus (MRSA) [7], or target-mediated resistance by gene transfer 
and recombination in naturally transformable bacterial strains as seen in Streptococcus pneumoniae [8,9] 
and Neisseria gonorrhoeae [10]. 
 
Figure 1. Peptidoglycan biosynthesis in bacteria, highlighting the membrane-associated 
stage and the several key enzymes discussed in this review. NAM represents N-acetylmuramic 
acid; NAG represents N-glucosamine, the repeating disaccharide motif of the peptidoglycan 
polymer; X represents the canonical 3-4 peptide crosslink between two stem peptides. 
Enzymes with available crystal structures are shown: MraY (PDB code: 4J72); MurG (PDB 
code: 1NLM); PgpB (PDB code: 4PX7). 
The enzymes in the bacterial peptidoglycan biosynthetic pathway have been explored as potential 
drug targets in detailed studies by many research groups and pharmaceutical companies in the past.  
Some natural products including fosfomycin and D-cycloserine target intracellular proteins in the 
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pathway, but issues of membrane permeability and effective intracellular concentrations have prevented 
development of high affinity inhibitor lead compounds [11]. However, the fact that peptidoglycan has 
no counterpart in mammalian cells minimises potential drug toxicity issues and makes it attractive,  
in theory, for the development of antimicrobial agents [12,13]. Peptidoglycan is a discontinuous,  
mesh-like, heteropolymeric macromolecule, either located outside the cytoplasmic membrane of  
Gram-positive bacteria or in-between the inner and outer membrane of Gram-negative bacteria. This 
fundamental component of the bacterial cell wall is indispensable for preserving cellular integrity by 
providing structural support, maintaining the cell shape, and protecting the cell from internal turgor 
pressure. It is essential that new cell walls be formed prior to the division process. If the formation of a 
functional cell wall is hindered, the cell division process can be effectively interrupted [14]. 
The biosynthesis of peptidoglycan can be generally divided into three stages (Figure 1).  
The first stage results in the synthesis of uridine diphosphate-N-acetylmuramyl-pentapeptide  
(UDP-MurNAc-pentapeptide) in the cytoplasm. This process is initiated in the cytoplasm, wherein  
UDP-N-acetylglucosamine (UDP-GlcNAc) is converted by MurA and MurB to UDP-N-acetylmuramic 
acid (UDP-MurNAc). The final cytoplasmic peptidoglycan precursor, UDP-MurNAc-pentapeptide,  
is generated by the sequential action of adenosine triphosphate (ATP)-dependent ligases, MurC through 
to MurF [15]. The second stage initiates with the joining of the soluble precursor to a membrane-bound 
undecaprenyl phosphate (C55-P) carrier lipid via the integral membrane protein MraY to form Lipid I on 
the intracellular face of the cell membrane. Lipid I is then glycosaminylated by a membrane-associated 
glycosyltransferase, MurG, with UDP-GlcNAc to yield Lipid II [16,17]. In Gram-positive species,  
Lipid II is modified by the aminoacylation of the ε-amino group of the third amino acid residue or the 
amidation of glutamate at position 2 to isoglutamine. These modifications have been shown to be 
essential for subsequent crosslinking [18]. Lipid II is translocated through the cytoplasmic membrane to 
enable the initiation of the third stage of peptidoglycan biosynthesis. Thereafter, Lipid II is polymerised 
by glycosyltransferase enzymes, including the essential class A PBPs, prior to peptide crosslinking via 
the transpeptidase activity of class A and B PBPs, to produce a highly crosslinked peptidoglycan 
structure [19,20]. It is these latter membrane-bound steps that may offer promise for future drug 
discoveries in peptidoglycan biosynthesis (Figure 1). The very recent discovery of the Gram-positive 
specific antibiotic teixobactin with no reported resistance mechanism that binds to Lipid II highlights 
the important role the lipid-linked metabolites play in the development of new antibacterial drugs [21]. 
This prompts a re-evaluation of the enzymatic route for Lipid II biosynthesis and its metabolism in light 
of recent advances in our understanding of the key enzymes involved, which is the subject of this review. 
2. The Formation of Lipid I by MraY 
MraY catalyses the formation of Lipid I by transferring the soluble, cytoplasmic-derived  
UDP-MurNAc-pentapeptide onto the C55 lipid carrier presented at the cytoplasmic membrane  
interface [22]. MraY belongs to the superfamily of polyprenyl-phosphate N-acetyl hexosamine  
1-phosphate transferase (PNPT) [23], including members like WecA, which catalyses the analogous 
function of transferring N-acetylglucosamine 1-phosphate (GlcNAc-1-P) onto the lipid carrier during  
the synthesis of enterobacterial common antigen and O-antigen lipopolysaccharide in Gram-negative 
bacteria [24]. 
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In the past, structural and functional studies of MraY have generally proven difficult using 
conventional overexpression and purification strategies for isolation of this integral membrane  
protein [22,25]. Whilst it is a multiple-membrane-spanning protein, MraY has both the amino (N-) and 
carboxyl (C-) termini located in the periplasmic region [26,27]. Attempts to purify quantities of MraY 
from Escherichia coli have met with low levels of overexpression in general, but the sufficient quantities 
of the Bacillus subtilis MraY were purified for study using radioactive-based detection systems [22,25] 
and Förster resonance energy transfer (FRET)-based assays have been developed for MraY to facilitate 
drug discovery [28]. 
In attempts to overexpress and purify MraY in its active form, Ma et al. reported the successful 
implementation of cell-free production of this protein from both E. coli and B. subtilis origin [29]. 
Interestingly, functional E. coli MraY can only be produced in the presence of membrane lipids, 
highlighting the importance of membrane lipids to yield a functionally folded and active enzyme.  
Roos et al. subsequently reported the co-translation of E. coli MraY with pre-formed nanodiscs in  
a cell-free expression system and managed to characterise its functional folding and activity [30].  
They discovered that the lipid head group chemistry and the degree of lipid saturation used in the 
nanodisc system will impact the functionality of MraY. 
Considering the challenges to overexpress and purify this membrane translocase, the first crystal 
structure of MraY was a landmark event in the field as described at 3.3 Å resolution by Chung et al. [31] 
(PDB code: 4J72, Figure 2). The protein structure was solved from the thermophilic bacterium  
Aquifex aeolicus due to its increased thermal and biochemical stability after screening 19 MraY proteins 
from different bacteria species. They demonstrated that A. aeolicus MraY crystallises as a dimer with a 
hydrophobic tunnel, postulated to be large enough to accommodate lipids at the centre of the dimer 
interface. Crosslinking studies conducted in both detergent micelle and lipid membrane conditions 
substantiated the oligomeric status of A. aeolicus MraY. 
The crystal structure is consistent with previous topological studies [26], with 10 transmembrane 
(TM) helices, an interfacial helix, a periplasmic β-hairpin, a periplasmic helix, and five cytoplasmic 
loops, with both N- and C-termini located in the periplasm. The crystal structure revealed that TM9  
splits into two helical fragments (termed TM9a and TM9b), whereby TM9b was deemed to protrude 
about 20 Å into the lipid membrane (away from the rest of the structure) with a 50° bend relative to the 
membrane normal [31]. The active site was postulated to be within the cleft established around the inner 
leaflet membrane region of TM8 when TM5 is surrounded by TM3, TM4, TM8, and TM9b [27,31]. 
Many of the polar and charged invariant residues identified in B. subtilis MraY by Al-Dabbagh et al. [27] 
were located within this cleft by mapping sequence conservation. The catalytic roles of D117, D118, 
D265, and H324 located in the putative active sites were inferred and supported by mutational studies 
(Figure 2). 
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Figure 2. Crystal structure of A. aeolicus MraY (PDB code: 4J72) showing a cutaway  
view from the cytoplasmic side, presenting the key active residues and the oval-shaped 
hydrophobic tunnel at the dimer interface said to be able to accommodate lipids. The MraY 
dimer (coloured only for one of the protomers) is shown in the top insert. The figure was 
prepared using UCSF Chimera version 1.10.1 [32]. 
It is known that Mg2+ is essential for the activity of MraY [25,27]. Based on similarity to the Mg2+ 
binding motif (DDXXD/N) of farnesyl diphosphate synthases, Lloyd et al. suggested that the aspartate 
pairs, D115 and D116 of E. coli MraY are involved in the binding of this divalent cation [25]. However, 
this notion was challenged by Al-Dabbagh et al. for the corresponding pairs, D98 and D99, in B. subtilis 
MraY [27]. Instead, they counter-suggested that D98 is involved in deprotonation of the lipid substrate. 
The D265 residue of A. aeolicus MraY was identified as the coordination site for Mg2+ through 
anomalous scattering studies [31]. An inverted U-shaped groove surrounding TM9b that extends into 
the active site harbouring D117, as revealed by surface representation of the A. aeolicus MraY crystal, 
was said to be the binding site for the membrane-embedded lipid carrier. The lipid carrier was  
considered to fit into this groove due to the elastic nature of its polyisoprenyl tail. Being surrounded by 
conserved charged residues like K121, K133, and D265, together with the Mg2+ cation, D177, which 
corresponds to D98 in B. subtilis MraY, was predicted to bind the phosphate moiety of C55-P [31].  
The fifth cytoplasmic loop of A. aeolicus MraY which contains a portion of TM9b (due to its  
protrusion) connects TM9b and TM10. The conserved sequence specific to the PNPT superfamily,  
i.e., the HHH motif, was identified in this region, which was speculated to be the binding site for  
UDP-MurNAc-pentapeptide [31]. 
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The catalytic mechanism of MraY is yet to be confirmed. A two-step mechanism was first proposed 
by Heydanek et al., involving the attack of an active site nucleophile upon the β-phosphate of the  
UDP-MurNAc-pentapeptide to form a covalent MurNAc-pentapeptide-phosphoenzyme intermediate, 
whilst releasing uridine monophosphate (UMP) [33]. It is then followed by the attack by an oxyanion 
from C55-P on the phosphoenzyme intermediate to regenerate the free MraY enzyme with the formation 
of Lipid I [25,34]. Alternatively, a one-step catalytic mechanism was put forward for MraY to involve a 
direct nucleophilic attack of the phosphate oxyanion of C55-P onto the β-phosphate of UDP-MurNAc-
pentapeptide, resulting in the formation of Lipid I, while releasing UMP in a single step [27]. 
The availability of a crystal structure can facilitate the studies of the structure-activity relationship of 
a target protein, serving as an important starting point for synthetic drug development [35,36]. Synthetic 
protein inhibitors with enhanced potency and efficacy can, in theory, be developed by probing into the 
atomic structure of the target enzyme, specifically the substrate-binding sites. The cytosolic enzymes 
involved in peptidoglycan biosynthesis, such as GlmS, GlmM, GlmU, and MurA-MurF that had been 
crystallised, have been the subjects of intense drug discovery efforts. However, whilst many inhibitors 
have been described, no major class of clinical candidate or licensed drug has been produced [11].  
The key membrane proteins reviewed here may harbour some interesting new targets, but challenges  
still prevail in terms of biochemical and biophysical studies of these proteins. To advance the knowledge 
of MraY, the critical membrane translocase that forms Lipid I, co-crystallisation involving its natural 
substrates (i.e., UDP-MurNAc-pentapeptide or C55-P) and/or other ligands, will reveal more information 
about the substrate-binding mechanism. 
MraY is the target for many classes of nucleoside natural product inhibitors, predominantly 
synthesised by the Streptomycetes, including mureidomycins, pacidamycins, napsamycins, and 
sansanmycins which belong to the peptidyl nucleosides class, and fatty acyl nucleosides like 
liposidomycins and caprazamycins. It is also inhibited by muraymycins (lipopeptidyl nucleosides) and 
nucleoside disaccharides, such as tunicamycins, streptovirudines, and corynetoxins, besides the 
capuramycins (glycosyl nucleosides). Over the years, these MraY inhibitors have been extensively 
reviewed [34,37] and thus will not be further discussed in this review. Although mureidomycins and 
muraymycins were found to be effective in animal models [34], none of these compounds are suitable 
for clinical use, due to issues of toxicity associated with a variety of eukaryotic membrane-associated 
glycosyltransferases [38]. A novel caprazamycin derivative, caprazene 4-butylanilide (CPZEN-45),  
is currently in the preclinical study phase for the treatment of tuberculosis [39] targets WecA in 
Mycobacterium tuberculosis and TagO in B. subtilis [40]. Both of these membrane proteins are 
orthologous and belong to the same PNPT superfamily as per MraY [23]. They are involved in the 
biosynthesis of mycolylarabinogalactan and wall teichoic acid, respectively. 
MraY is also targeted by the lysis protein E from bacteriophage ΦX174 [34]. The interaction of lysis 
protein E with MraY was found to be mediated by the host peptidyl-prolyl isomerase SlyD [34,41].  
The F288L mutation in E. coli MraY, which is located on TM9, can confer resistance to the lysis protein 
E [42]. Interestingly, the substantial protrusion in TM9 revealed in the A. aeolicus MraY crystal structure 
positions the corresponding F288 residue in TM9a, close to the outer face of the cytoplasmic membrane. 
Together with E287, these two residues were said to interact with lysis protein E which harbours the 
RWXXW motif, and is also found on many other cationic antimicrobial peptides [31,43]. 
  
Antibiotics 2015, 4 501 
 
 
3. The Formation of Lipid II by MurG 
MurG is the membrane-associated glycosyltransferase that catalyses the next lipid-linked step by 
transferring GlcNAc from UDP-GlcNAc to the C4 hydroxyl of the membrane-anchored Lipid I to form 
Lipid II [44]. In contrast to MraY, MurG is a soluble protein working at the cytoplasmic membrane 
surface in order to access its membrane-bound Lipid I substrate. The first MurG crystal structure from  
E. coli was solved by Ha et al. at a resolution of 1.9 Å [44] (PDB code: 1F0K). Subsequently, the  
UDP-GlcNAc-bound crystal of E. coli MurG was solved at 2.5 Å by the same group [45] (PDB code: 
1NLM, Figure 3). These structures were joined by that of the Pseudomonas aeruginosa protein, bound 
to the sugar substrate, by Brown et al. at 2.2 Å resolution (PDB code: 3S2U, Figure 3). 
 
Figure 3. (A) Comparison of MurG from E. coli (orange, PDB code: 1NLM) and  
P. aeruginosa (blue, PDB code: 3S2U), showing that both structures display high structural 
similarity despite sharing only 45% sequence similarity. The G-loops (coloured according 
to bacterial origin) proposed to stabilise negatively charged phosphates from Lipid I  
and UDP-GlcNAc are shown; (B) E. coli and (C) P. aeruginosa MurG in complex with 
UDP-GlcNAc (red), with key residues being highlighted; the Lipid I-binding N-terminal 
domain is coloured in orange, while the UDP-GlcNAc-binding C-terminal domain is 
coloured in blue. The figure was prepared using UCSF Chimera version 1.10.1 [32]. 
MurG belongs to the glysosyltransferase B superfamily, whose activity is independent of any metal 
ions [45,46]. MurG utilises a sequential ordered Bi-Bi mechanism whereby the donor substrate,  
UDP-GlcNAc binds to the enzyme first, before the acceptor Lipid I is recruited to the enzyme for the 
sugar transfer reaction to occur [45]. Crystal structures revealed that MurG is composed of two domains, 
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linked by a hinge region, separated by a deep cleft of about 20 Å deep and 18 Å across its widest  
point [44]. The width of the cleft was noted to reduce by 2 Å when the UDP-GlcNAc is bound, with the 
enzyme adopting a more closed conformation [45]. 
The C-terminal domain of MurG harbours the binding site for UDP-GlcNAc, while Lipid I binds to 
the N-terminal domain. MurG is predicted to associate with the inner leaflet of the cytoplasmic 
membrane through its N-terminal hydrophobic patch, which is surrounded by basic residues, next to the 
Lipid I binding site (Figure 3). This membrane association is thought to be driven by both hydrophobic 
and electrostatic interactions with the negatively charged lipid membrane [44]. In the P. aeruginosa 
MurG co-crystal with UDP-GlcNAc, the membrane-association region is disordered. Brown et al. thus 
hypothesised that the interaction with the acceptor Lipid I is probably needed to stabilise MurG in this 
region [47]. Both the N- and C-domains of MurG present a characteristic Rossmann fold (with α/β  
open-sheet motif), which is a signature to nucleotide-binding domains, presenting three conserved 
glycine-rich stretch of amino acids (termed the G-loops), proposed to stabilise the negatively charged 
phosphates from the substrates, independent of any metal ions [45] (Figure 3). Sequence alignment of 
MurG homologues pinpointed that the invariant residues are located at or near the cleft between the two 
domains, thus placing the active site likely along that region [44,47,48]. 
Despite sharing only 45% overall sequence similarity, MurG from P. aeruginosa shares many 
common features with its E. coli counterpart, and their crystal structures were reported to overlap  
closely [47] (Figure 3). The substrate-binding mode of P. aeruginosa MurG is said to resemble that of 
conformer A in E. coli as described by Ha et al. [44]. By comparing their crystal structures (PDB codes: 
1NLM vs. 3S2U), Brown et al. noted that the C-terminal domain of the E. coli MurG moves away from 
the N-terminal domain by approximately 15° about the inter-domain hinge, resulting in a significantly 
wider cleft, displacing the UDP-GlcNAc substrate by about 6 Å [47]. The amide group of G14 in  
P. aeruginosa MurG can form a hydrogen bond to the α-phosphate oxygen of UDP, placing the  
β-phosphate near to the N-terminal helix 1. This facilitates favourable interaction between the helix 
dipole with the negatively charged phosphate. In contrast, the equivalent G17 in E. coli MurG is 
positioned closer to the C6-hydroxyl group of the UDP cofactor. This difference is said to stabilise the 
more closed morphology of the cofactor binding site in E. coli MurG [47] (Figure 3). 
The critical residues T16, H19, Y106 identified in E. coli MurG to bind Lipid I are also present in the 
P. aeruginosa MurG co-crystal complex, namely T12, H15, and Y102 in equivalent (Figure 3). These 
residues were found to be invariant in other MurG homologues across bacterial species. In particular, 
the H19 residue located close to the bound UDP-GlcNAc and the proposed Lipid I binding site might be 
involved in anchoring the polyisoprenyl tail of the C55-P acceptor [47]. To propel further structural 
insight in terms of substrate binding and catalytic mechanism, a co-crystal structure of MurG with the 
Lipid I substrate is required. 
Known inhibitors to the glysosyltransferase enzymes typically possess the nucleoside moiety. 
Trunkfield et al. reported the synthesis of uridine-linked transition state mimics, in which 10 of 18 
compounds demonstrated inhibition towards E. coli MurG in vitro [49]. On the other hand, the 
phenotypic screening of small synthetic compounds to potentiate the activity of β-lactams to MRSA led 
to the discovery of a steroid-like compound named murgocil by Mann et al. [50]. This compound was 
found to selectively hinder peptidoglycan biosynthesis in S. aureus cells by the inhibition of MurG.  
In the presence of murgocil, Lipid II synthesis was reduced in a dose-dependent manner and stable 
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murgocil-resistant mutants were found to map to single non-synonymous mutations in MurG.  
The four identified mutation sites are located near the uracil binding pocket, lining the cleft between the 
two domains. In silico structural modeling using the E. coli MurG co-crystal structure as a template 
demonstrated that murgocil binds to the deep cleft separating the two domains of the enzyme. It was 
postulated to compete with the binding site of UDP-GlcNAc, which may lock the enzyme into a rigid, 
non-active form [50]. 
Murgocil was shown to not affect the membrane association of MurG. It was previously reported that 
Lipid II mediates the localisation of the class A bifunctional PBP2 in S. aureus [51]. Mann et al. observed 
that PBP2 was highly delocalised in murgocil-treated cells and the delocalisation was demonstrated to 
be murgocil-dependent, not as a result of the general disassembly of the divisome [50]. In essence, 
murgocil-dependent delocalisation of PBP2 involves the depletion of Lipid II rather than the disruption 
of the FtsZ ring. The synergistic effect of murgocil towards β-lactams can be explained by the 
delocalisation of PBP2 that renders the cells more susceptible to reduced level of β-lactams to neutralise 
the remaining functional PBP2 at the septum. The activity of murgocil is specific but restricted to the 
Gram-positive Staphylococci in this study as murgocil lacks bioactivity towards other bacterial species 
tested [50]. 
4. The Identity of the Lipid II Flippase 
Following the formation of Lipid II, this key lipid-linked peptidoglycan building block is translocated 
(flipped) across the cytoplasmic membrane for the subsequent reaction by the peptidoglycan synthases. 
The metabolism of Lipid II must be a rapid and continuous process, as calculations have estimated that 
there are only a few hundred molecules of Lipid II present in the cell membrane at any time [17].  
In addition, we know that the carrier lipid C55-P is used in a number of other membrane-specific 
metabolic processes, setting an imperative for its rapid recycling and utilisation [52]. The identity of the 
flippase(s) for Lipid II has been a contentious subject in the field for decades, and in the past few years 
two distinct schools of thought have dominated the field. 
4.1. Contender I: FtsW  
In the search for the flippase, Mohammadi et al. were the first group to demonstrate biochemically 
that the translocation of Lipid II involves FtsW by exploiting fluorescence and FRET-based assays [53]. 
FtsW is an essential polytopic membrane protein in E. coli and many other species [54–56]. Even though 
the crystal structure of FtsW is currently unavailable, the topology of this protein from E. coli and  
S. pneumoniae, which contain 10 predicted transmembrane helices, has been mapped [54,55]  
(Figure 4). Importantly, FtsW constitutes a core element of the divisome and had been shown to move 
to the septum during cell division in E. coli and interact with two PBPs, i.e., the class A bifunctional 
PBP1B that utilises Lipid II directly and the class B transpeptidase PBP3 (also known as FtsI), through 
the periplasmic loop in-between TM9 and TM10 (Figure 4). This observation was demonstrated by 
various biochemical techniques including protein-protein interaction assays [57–59]. In addition, the 
gene encoding for FtsW is located on the same division and cell wall (dcw) cluster, in close proximity 
to MurG and PBP3 [54,55]. 
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Figure 4. Two-dimensional topology representation for (A) FtsW and (B) MurJ from E. coli, 
generated based on the topological information presented by Lara and Ayala [54] for  
FtsW and Butler et al. [60] for MurJ, respectively. The several proposed key residues and 
transmembrane segments important for the putative function of both proteins are highlighted. 
A group led by Eefjan Breukink (Utrecht University) had previously established that the translocation 
of Lipid II is neither a spontaneous flip-flop process utilising its undecaprenyl chain, nor is it induced 
by the presence of helical transmembrane peptides. The formation of Lipid II is also not coupled to its 
simultaneous translocation across the cytoplasmic membrane and MurG does not mediate this 
translocation [61]. Using E. coli membrane vesicles, they showed that the transport of Lipid II does not 
depend on energy sources like ATP or proton motive force, which led to the conclusion that the 
translocation of Lipid II does not involve any ATP-binding cassette (ABC)-like transporter. However, 
the flipping of Lipid II across the membrane bilayer is directly linked to the downstream 
transglycosylation activity whereby the disaccharide-pentapeptide moiety is attached onto existing 
glycan chains which may drive the reaction by a mass action principle [61]. 
They went on to demonstrate that the overexpression of both E. coli and S. pneumoniae FtsW 
considerably increased Lipid II translocation across the bacterial membranes using fluorescently labelled 
Lipid II. Purified FtsW proteins reconstituted in the model membrane system were also capable of 
flipping the derivatised Lipid II [53]. On the contrary, control proteins like MraY and MurJ [62] did not 
result in the same observed Lipid II translocation phenomenon. When the experiments were repeated 
with bacterial membranes depleted of FtsW, they observed a reduction (but not abolishment) in Lipid II 
translocation, supporting the role of FtsW as the putative Lipid II flippase. The remaining transport 
activity was suggested to be the presence of the FtsW homologue RodA in the membranes [53]. 
To further elucidate the role of FtsW as the Lipid II flippase, Mohammadi et al. discovered that the 
TM4 of FtsW is required for the translocation, in particular two charged residues, R145 and K153, within 
this transmembrane segment by mutational studies [63] (Figure 4). The two mutants were not able to 
complement an E. coli FtsW temperature-sensitive strain at the non-permissive temperature (42 °C), 
hinting at an impairment in cell wall assembly, which is consistent with the postulated function of FtsW 
as the Lipid II flippase. However, the same mutations did not affect the localisation of FtsW to the 
division septum [63]. By studying Lipid II analogues differing in sizes and head groups, a size-restricted 
pore-like structure in FtsW was suggested to accommodate the putative lipid-linked substrate. A particular 
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analogue with a polyethylene glycol (PEG) linker was successfully transported by FtsW, indicating that 
branched stem peptide Lipid II molecules, including the pentaglycine side chain found in S. aureus Lipid 
II, can be accepted [63]. 
FtsW was also shown to facilitate the transmembrane movement of different phospholipids, such as 
phosphatidylethanolamine, phosphatidylglycerol, and phosphatidylcholine, which are common during 
membrane biogenesis, thus supporting the previous notion that the biosynthesis of peptidoglycan 
requires ongoing phospholipid synthesis [63,64]. Nonetheless, the two specific charge residues, R145 
and K153, in TM4 were not required for this activity and no headgroup specificity was displayed by 
FtsW in terms of phospholipid translocation [63]. They proposed that given the putative role of FtsW as 
the Lipid II flippase (during cell division), other members of the shape, elongation, division, and 
sporulation (SEDS) superfamily such as RodA and SpoVE might also participate in the translocation of 
Lipid II during cell elongation and sporulation, respectively [64,65]. However, further experimental 
evidence is needed to substantiate this inference. 
4.2. Contender II: MurJ  
MurJ (previously designated as MviN) was first identified by Natavidad Ruiz (Ohio State University) 
through a bioinformatics screen in search of the Lipid II flippase in E. coli [62]. MurJ,  
found to be essential in E. coli, belongs to the multidrug/oligosaccharidyl-lipid/polysaccharide (MOP) 
exporter superfamily, wherein some members within this family had been shown mechanistically  
as transporters [66]. This discovery was independently supported from experimental findings by  
Inoue et al. around the same time [67]. Subsequently, the MurJ homologue in Burkholderia cenocepacia, 
BCAL2764, was identified by Mohamed and Valvano, and found to be essential for survival, akin to the 
E. coli counterpart [68]. The E. coli and B. cenocepacia cells depleted of MurJ, in which protein 
expression was under the control of an inducible promoter [62,68] or controlled by use of a 
thermosensitive mutant [67], became heterogenous in shape, leading to the formation of ghost cells and 
eventual lysis. The BCAL2764-depleted strain also became sensitised to β-lactams [68]. 
The MurJ-depleted cultures only synthesised about one-third of the amount of mature peptidoglycan, with 
concurrent accumulation of the peptidoglycan lipid and nucleotide precursors [62,67,68]. Utilising a 
radiolabelled assay, the accumulation of Lipid II intermediates was observed in the thermosensitive MurJ 
mutant, pointing to its role in the metabolism of the lipid intermediates of peptidoglycan biosynthesis. 
The growth defect was suppressed with the overexpression of undecaprenyl pyrophosphate (C55-PP) 
synthase (UppS), a cis-prenyltransferase that supplies the cells with the C55 carrier lipids (in 
pyrophosphate form) [67]. The two MurJ proteins from E. coli and B. cenocepacia were demonstrated 
to be functionally similar, by reciprocal complementation experiment, in restoring the viability in 
conditional mutants of both species [68]. 
Like FtsW, the topology for E. coli MurJ had been mapped, consisting of 14 transmembrane domains, 
with both its N- and C-termini in the cytoplasm [60] (Figure 4). In the absence of the crystal structure 
for MurJ, Butler et al. generated a structural model for E. coli MurJ based on several crystallised 
members of the MOP exporter superfamily in silico [60]. The structural model of MurJ revealed a 
solvent-exposed cavity with overall positive charge, lined by TM1, TM2, TM7, and TM8 within the 
plane of the cytoplasmic membrane. Specific charged residues within this central cavity, i.e., R18 and 
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R24 (TM1), R52 (TM2), R270 (TM8), and D39 (periplasmic loop 1), were demonstrated by mutational 
studies to be essential for the function of MurJ (Figure 4). This central cavity architecture of MurJ is 
said to be conserved among the crystallised members of the multidrug and toxic compound extrusion 
(MATE) transporters family (part of the MOP exporter superfamily), suggesting similar transport 
function. MurJ was predicted to adopt an outward-opened conformation with two side portals that open 
into the periplasmic space [60]. 
An analogous structural model generated for BCAL2764 in B. cenocepacia also exhibited the 
characteristic central cavity with essential charged residues at the same region as reported in E. coli  
MurJ [68]. By abolishing the charges on R18, R24, and R274 on BCAL2764, a non-functional  
protein was resulted, which is akin to the observation by Butler et al. [60,68]. However, BCAL2764 is 
still functional when the charges were abolished on D39 and R52, in contrast to E. coli MurJ. The eight 
charged residues found in E. coli MurJ (within TM1, 2, 8, and periplasmic loop 1) were further studied 
by Butler et al. [69]. In particular, they found that D39 is essential for the biogenesis (possibly for 
membrane insertion) and function of MurJ. They also explored the conservation of these eight residues 
on the Gram-positive homologue YtgP in Streptococcus pyogenes [70], and found that only three were 
similarly positioned and vital for function. They hypothesised that some of the charged residues located 
within the central cavity are driving the interaction with Lipid II, and are possibly involved in some sort 
of energy coupling during the transport process [69]. 
Sham et al. presented the in vivo evidence that MurJ is the Lipid II flippase [71]. By treating the  
E. coli cells with colicin M (which specifically cleaves the disaccharide-pentapeptide moiety from the 
C55 carrier lipid), the level of the soluble colicin M product was reduced upon MurJ inactivation, and in 
contrast, the accumulation of lipid-linked peptidoglycan precursors was observed. They concluded that 
the inactivation of MurJ protected Lipid II resulted from the action of colicin M either through the 
blocking of Lipid II translocation or by interfering with the import or activity of colicin M. By removing 
the outer membrane of the E. coli cells through spheroplasting, and thus providing direct access for 
colicin M to the flipped Lipid II, the level of soluble colicin M product was not restored, supporting 
MurJ as the Lipid II flippase [71]. In stark contrast to the in vitro findings by Mohammadi et al. [53,63], 
Sham et al. observed that, in the E. coli-null RodA mutant depleted of FtsW, the translocation of Lipid 
II was relatively unperturbed, suggesting that these two SEDS proteins are not involved in the transport 
of Lipid II. However, they observed a reduction in the level of peptidoglycan lipid intermediates in this 
mutant, implicating that the loss of these SEDS proteins might have an effect on the recycling of C55-P 
or the synthesis of peptidoglycan precursors [71]. 
MurJ was found to be highly conserved among the Gram-negative Proteobacteria, but not for the 
Gram-positive Firmicutes. YtgP, the closest functional homologue to MurJ, is however, conserved in 
the Gram-positive Firmicutes. The S. pyogenes YtgP (Spy_0390) was found to complement a  
MurJ-depleted strain of E. coli [70]. Whilst being essential in S. pneumoniae and S. aureus, YtgP is not 
essential in the Gram-positive model organism B. subtilis, alluding to the presence of other functional 
homologues. Besides YtgP, the other members in the MOP exporter superfamily, namely SpoVB, YkvU, 
and YabM, were also identified as putative MurJ homologues. Similarly, they were not found to be  
essential in B. subtilis. Mutant cells lacking these proteins did not display the vegetative defects expected 
if they serve as the Lipid II flippase like MurJ [72,73]. 
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Fay and Dworkin showed that E. coli MurJ was able to complement the sporulation defects in  
B. subtilis cells lacking SpoVB and restored spore production. On the other hand, basal expression of 
SpoVB and YtgP (in the non-induced state) complemented the growth defect in a MurJ-depleted strain 
of E. coli, but not when the two genes were fully induced [72]. The observation that these two MurJ 
homologues were not essential in B. subtilis led to the speculation that they might be playing an 
accessory role or are involved in an alternate pathway of peptidoglycan biosynthesis, i.e., flipping  
lipid-linked precursors, but not necessarily with Lipid II. They could also be involved in the process of 
cell wall modification, in which the C55 lipid carrier is utilised [72,73]. This offered a possible 
explanation regarding the lethality being observed when YtgP and SpoVB were fully induced in E. coli 
cells depleted of MurJ, due to the sequestration of the C55 isoprenoid chain [72]. 
Meeske et al. further investigated the knockout effect of all 10 MOP exporter superfamily members 
in B. subtilis, including YtgP, SpoVB, YkvU, and YabM [74]. The existence of an alternate flippase was 
alluded to when the decuple mutant was shown to be viable with a similar growth rate as the wild types, 
with only minimal morphological defects. An uncharacterised gene, ydaH (being renamed to amj, 
representing an “alternate to MurJ”), was discovered thereafter to be the synthetic lethal pair to YtgP in  
B. subtilis. When both Amj and YtgP were depleted in B. subtilis, aberrant cell morphologies and 
extensive cell lysis were observed, analogous to the phenotype of MurG knockdown. Amj was also 
demonstrated to complement E. coli cells lacking MurJ. In addition, the expression of either B. subtilis 
YtgP or Amj in E. coli cells can support the transport of Lipid II across the cell membrane when the 
native MurJ is inactivated, using the same colicin M flippase assay as per Sham et al. [71,74]. Being 
only half the size of typical MOP exporter superfamily members, Amj (predicted to contain only  
six transmembrane segments) is hypothesised to dimerise to form the channel for Lipid II transport in 
line with the charged central cavity reported in E. coli MurJ [60,74]. 
Last but not least, SAV1754, the MurJ homologue in S. aureus, was identified by Huber et al. via  
a chemical genetic approach utilising high throughput screening of a synthetic chemical library for 
compounds to restore the activity of carbapenem class β-lactams against MRSA [75]. Two structurally 
related indole compounds, 3-{1-[(2,3-Dimethylphenyl)methyl]piperidin-4-yl}-1-methyl-2-pyridin-4-yl-
1H-indole (DMPI) and 2-(2-Chlorophenyl)-3-[1-(2,3-dimethylbenzyl) piperidin-4-yl]-5-fluoro-1H-
indole (CDFI), were discovered to selectively target SAV7154. Fluorescent staining of nascent 
peptidoglycan revealed that S. aureus cells treated with both compounds displayed a significant 
reduction in overall fluorescence of new cell wall material and a low level of cells showed clear septum 
staining. The genetic inactivation of SAV1754 resulted in pronounced hypersensitivity towards  
β-lactams, exceeding the effect of PBP2 inactivation. They asserted that SAV1754 is not likely to play 
a role in drug import or efflux because the three resistant mutants only conferred marked resistance to 
the above-mentioned indole compounds without cross-resistance to other cell wall inhibitors tested such 
as vancomycin, fosfomycin, and moenomycin [75]. Key features of the two different proposed Lipid II 
flippase proteins are summarised in Table 1. 
The identity of the Lipid II flippase(s) remains hitherto a “Holy Grail” in bacterial cell wall biology 
to complete a core understanding of the lipid-linked stage of peptidoglycan biosynthesis. Given the high 
metabolic requirement for Lipid II and its carrier lipid, the possibility that the transport of Lipid II 
involves more than one protein should also be given fair consideration. Structural elucidation of the two 
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contending protein families will provide a vital part of this investigation and may offer more insight into 
the translocation mechanism involved and possibly the energy source used in this remarkable process. 
Table 1. Comparison of the two major Lipid II flippase contenders. 
Protein Key Features 
FtsW 
• Essential and conserved among cell wall synthesising eubacteria such as E. coli [54–56] 
• Topology mapped for E. coli and S. pneumoniae, with 10 TM helices, both N- and C-termini in 
the cytoplasm [54,55] 
• Demonstrated to interact with PBP3 (FtsI) and PBP1B through periplasmic loop between TM9 
and TM10 [57–59] 
• Demonstrated to flip fluorescently labelled Lipid II in vitro using bacterial and model 
membranes [53], R145 and K153 on TM4 are implicated in the translocation of Lipid II [63] 
• Demonstrated to flip phospholipids and can accommodate modified Lipid II with a PEG linker [63] 
• SEDS superfamily homologues RodA and SpoVE suggested for similar translocation function in 
cell elongation and sporulation respectively [64,65] 
MurJ 
• Broadly conserved in eubacteria and essential for bacteria such as E. coli and 
B. cenocepacia [62,67,68] 
• Topology mapped for E. coli MurJ with 14 TM helices, both N- and C-termini in the 
cytoplasm [60] 
• Structural model generated in silico for E. coli and B. cenocepacia MurJ, harbouring a central 
hydrophilic cavity with charged resides such as R18, R24, and R270/R274 implicated for substrate 
binding and transport function [60,68,69] 
• Demonstrated to flip radiolabelled Lipid II in vivo [71] 
• Functional MOP exporter superfamily homologues like YtgP and SpoVB are not essential in 
B. subtilis [72,74] 
• Alternative flippase: Amj discovered to form synthetic lethal pair to YtgP in B. subtilis and 
demonstrated to flip Lipid II [74] 
5. The Metabolism of C55-P: Multiple Enzymes Can Dephosphorylate C55-PP 
Undecaprenyl pyrophosphate is formed de novo on the cytoplasmic side of the cell membrane via the 
successive addition of eight isopentyl pyrophosphates (in cis configuration) onto a molecule of farnesyl 
pyrophosphate (in trans configuration) catalysed by the cytosolic enzyme UppS [76]. The resulting  
C55-PP would have to be dephosphorylated into the monophosphate form to be used as the active carrier 
molecule in the biosynthesis of peptidoglycan and other cell wall polysaccharides, including teichoic 
acids, lipopolysaccharides, and enterobacterial common antigens [6,16,52]. Thus, the metabolism of this 
limited yet common glycan lipid shuttle remains a crucial control point to prevent any imbalance in the 
formation of the bacterial cell envelope. The current knowledge, mechanism, and metabolism 
surrounding the C55 carrier lipid were recently reviewed in depth by Manat et al. [52].  
UppP (previously known as BacA) was demonstrated by El Ghachi et al. in their biochemical studies 
to be the primary phosphatase that acts on C55-PP in E. coli, accounting for 75% of total cellular C55-PP 
dephosphorylation [77]. E. coli UppP requires divalent metal ions such as Mg2+ or Ca2+ for activity, in 
order to coordinate the pyrophosphate moiety of C55-PP and facilitate nucleophilic attack by making the 
pyrophosphate a better leaving group [77,78]. They proposed that UppP takes part in the de novo 
biosynthetic pathway to generate C55-P by dephosphorylating C55-PP formed by UppS, thus suggesting 
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that it acts on the cytosolic face of the cell membrane. This supposition is fueled by the prediction of a 
large cytosolic loop that is conserved among UppP homologues, based on a seven TM helices model, 
coupled with the cytosolic location of UppS which supplies the C55-PP substrate [79,80]. In addition, the 
formation of Lipid I was evident when UppP was coupled to MraY [77]. 
However, Chang et al. [78] recently questioned this view by presenting evidence that UppP acts at 
the periplasmic side of the cell membrane. They demonstrated that the active site of E. coli UppP actually 
faces the periplasm based on their in silico structural model, validating it with a molecular dynamics 
simulation and mutational studies. The molecular modelling data suggested that the pyrophosphate 
moiety of C55-PP sits in the active site pocket surrounded by E17, E21, and R174 (Figure 5), whereas 
part of its C55 chain is situated in a hydrophobic surface in TM2 which facilitates the rearrangement of 
the long isoprenyl chain of C55-PP. The remaining hydrocarbon tail is highly flexible and oriented 
towards the phospholipid bilayer, akin to the observation of MraY with an inverted U-shaped 
hydrophobic groove predicted to house the lipid-linked substrate [31,78]. They went on to propose a 
catalytic mechanism for UppP involving H30 to initiate the nucleophilic attack on the C55-PP substrate; 
E17 or E21, on the other hand, may interact with the pyrophosphate moiety of C55-PP through the Mg2+ 
ion. In the putative phosphate binding loop (with the PGXSRSXXT motif), R174 can establish a 
hydrogen bond with the hydroxyl group of the pyrophosphate moiety [78] (Figure 5). 
 
Figure 5. Two-dimensional topology representation for UppP/BacA from E. coli,  
generated based on the topological information of the eight TM helices model presented by 
Chang et al. [78]. The several proposed key residues involved in the binding and catalysis of 
C55-PP are highlighted. The active site of this enzyme is proposed to face the periplasm. 
The overexpression of E. coli UppP was reported to result in bacitracin resistance by rapidly 
exhausting the cellular pool of C55-PP. Bacitracin, which is a group of cyclic polypeptide antibiotics, 
works by sequestering C55-PP, thereby preventing its dephosphorylation to occur [77,81,82]. The UppP 
homologue in Enterococcus faecalis, EF2439, was identified by Shaaly et al. and found to confer low 
level bacitracin to E. faecalis [83]. Similar to the E. coli UppP mutant, the EF2439 mutant displayed no 
observable growth phenotype in terms of growth rate, colony morphology, and biofilm formation in  
E. faecalis. However, reduced bacitracin tolerance was detected with the mutant [83]. Interestingly,  
Kjos et al. identified UppP as the target for lactococcin G, a class IIb two-peptide bacteriocins targeting 
Lactococcus lactis [84]. Exploiting whole genome sequencing, all 12 lactococcin G-resistant mutants 
were found to exhibit mutations in or near the gene encoding for UppP. These mutants were also resistant 
to the related bacteriocin, i.e., enterocin 1071. This similar degree of resistance observed suggests that 
UppP is the target of both lactococcin G and enterocin 1071. In addition, the expression of L. lactis UppP 
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in S. pnenumoniae cells, which are normally insensitive to lactococcin G and enterocin 1071, had 
sensitised the cells to these two bacteriocins [84]. 
Given the fact that the dephosphorylation activity of UppP does not account to 100% and the bacA 
gene is not essential in E. coli, it signifies the presence of other phosphatases that functionally 
complement UppP [79,82,85]. Upon the translocation of Lipid II across the cell membrane, the C55 lipid 
carrier (now in the pyrophosphate form) has to be dephosphorylated before being recycled back to the 
cytoplasmic side of the cell membrane to be reused [79,86]. One can thus envisage the need for C55-PP 
phosphatase activity at the periplasmic side to facilitate the recycling of this important but limited shuttle 
molecule. El Ghachi et al. identified three other integral membrane proteins, namely PgpB, YbjG, and 
YeiU, in E. coli that displayed C55-PP phosphatase activity and whose overexpression also contributed 
to bacitracin resistance. The genes encoding these three enzymes can be individually disrupted without 
any apparent growth defect in vivo, but the triple deletion of the bacA, pgpB, and ybjG, genes posed a 
lethal effect on E. coli [82]. 
Surprisingly, the overexpression of YeiU was not able to rescue the cell viability of the 
thermosensitive conditional triple mutant (with UppP expression restricted at 42 °C), despite the fact 
that its overexpression had resulted in a significant dephosphorylation of C55-PP [82]. Subsequently, the 
phosphotransferase function of YeiU (being then renamed to LpxT) was discovered by Touzé et al. to 
transfer the β-phosphate from C55-PP to Lipid A, forming Lipid A 1-diphosphate, thus connecting  
C55-P metabolism to Lipid A remodeling [87]. Similarly, PbrB was biochemically characterised to 
desphosphorylate C55-PP in Cupriavidus metallidurans with additional phosphotransferase function [88]. 
It transfers the phosphate group from C55-PP to the extruded lead ions (by the action of PbrA,  
an efflux pump for divalent metal ions), which results in lead precipitation, thus conferring lead resistance 
to the bacteria. 
PgpB, YbjG, and LpxT belong to the type 2 phosphatidic acid phosphatase (PAP2) superfamily, 
which is distinct to UppP [79,85]. Another member of the PAP2 superfamily is BrcC (previously known 
as YwoA) from B. subtilis, whose overexpression confers bacitracin resistance, with significant 
elevation of C55-PP phosphatase activity [81]. These PAP2 members displayed the consensus motif of 
the acid phosphatase domain, with signature residues facing the periplasmic region [79]. The three 
distinct motifs were designated as C1: “KX6RP”; C2: “PSGH”; and C3: “SRX5HX3D” [89]. 
Among these integral membrane PAP2 members, PgpB is considered the most characterised. Initially 
discovered for its phosphatase activity towards phosphatidylglycerolphosphate, phosphatidic acid, and 
lysophosphatidic acid [90–92], PgpB was subsequently found to act on diacylglycerol pyrophosphate [93] 
and undecaprenyl pyrophosphate [82]. The biochemical studies conducted on PgpB from E. coli 
demonstrated a broad substrate spectrum, and diacylglycerol pyrophosphate was considered the 
preferred substrate for PgpB in vitro and was able to stimulate the activity of PgpB on C55-PP in a  
dose-dependent manner [85]. Similarly, other common phospholipids in E. coli, such as phosphatidylglycerol, 
phosphatidylethanolamine, and cardiolipin, contributed to the same stimulation effect in vitro. Touzé et al. 
reasoned that the C55-PP substrate might have adopted a non-native conformation or orientation in the 
detergent micelles containing PgpB, thus preventing the charged head group to be presented to the active 
site of the enzyme. The input of phospholipids in this case could have rendered the detergent micelles 
more native membrane-like, and thus stimulated the activity of PgpB towards C55-PP [85]. The substrate 
promiscuity of PgpB could serve as a link between C55-P and phospholipid metabolism. 
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With the crystal structure of E. coli PgpB being solved recently at 3.2 Å by Fan et al., structural 
elucidation of this enzyme was facilitated [94] (PDB code: 4PX7, Figure 6). A double point mutant 
which showed identical properties to the wild-type enzyme was used for crystallisation. E. coli PgpB 
was found to display a similar folding topology and nearly identical active site to the other soluble PAP2 
enzymes, but it differs in terms of its substrate-binding mechanism. The binding of lipid substrates is 
deemed to proceed with an induced fit mechanism. The potential substrate entrance is the cleft formed 
by a V-shaped transmembrane helix pair, TM2 and TM3, allowing lateral movement of the lipid  
substrate to enter the active site from the phospholipid bilayer (Figure 6). The catalytic site of this 
enzyme was proposed to be near the solvent-membrane interface facing the periplasm, with the 
periplasmic opening side being over 10 Å wide [94]. 
 
Figure 6. Crystal structure of E. coli PgpB (PDB code: 4PX7) showing the proposed  
V-shaped cleft formed by TM2 and TM3 (highlighted in yellow) for the membrane-associated 
lipids to enter the enzyme active site facing the periplasmic region. The key catalytic  
residues discussed are presented here. The figure was prepared using UCSF Chimera version 
1.10.1 [32]. 
With respect to the catalytic mechanism for PgpB (and in reference to other PAP2 enzymes), it was 
proposed that the nucleophilic attack of the β-phosphate of C55-PP would be performed by a conserved 
histidine residue in motif 3 (Figure 6). This produces a phosphoenzyme intermediate that is stabilised 
by neighbouring arginine residues from the same motif and several other residues in motif 1 and 2 to 
hold the phosphate group close to the catalytic histidine in motif 3 [79]. Fan et al. suggested H207 and 
D211 in E. coli PgpB to form a charge-relay pair for the nucleophilic attack and formation of the 
phosphoenzyme intermediate, which is stabilised by the H163 that catalyses the cleavage of the 
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phosphate group [94] (Figure 6). The lipid substrate is said to position its phosphate head into the bottom 
of the active pocket and towards the nucleophilic H207 to form the phosphoenzyme complex, allowing 
H163 to complete the second step of dephosphorylation by recruiting a water molecule from the  
solvent-accessible side of the enzyme active site. R104 is said to interact with H207 and potentially with 
the substrate, while R201 is deemed to interact with H163 (Figure 6). Last but not least, the N-terminal 
of TM4 is potentially involved in the binding of the phosphate group in a charge-dipole interaction as 
the lack of side chain of G162 at the N-terminal of this transmembrane helix favours the binding of the 
phosphate group [94] (Figure 6). Key features of UppP in comparison to several PAP2 members are 
summarised in Table 2. 
Table 2. Comparison of UppP/BacA with the three members in PAP2 superfamily. 
Protein Key Features 
UppP/BacA 
• Suggested to be the primary C55-PP phosphatase in E. coli (75% of total cellular 
activity) [77] 
• Topology and structure modelled in silico with eight TM helices, both N- and C-
termini in the cytoplasm [78] 
• Active site predicted to face the periplasm, with key residues E17, E21, H30, and 
R174 based on in silico modelling [78] 
• Dependent on metal ions for activity [77,78] 
• Target for bacteriocins [84] but conferred bacitracin resistance when 
overexpressed [77,83] 
PA
P2
 su
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PgpB 
• Demonstrated activity toward phosphatidylglycerolphosphate, phosphatidic acid, 
lysophosphatidic acid [90–92], diacylglycerol pyrophosphate [93], and C55-PP [82] 
• Topology mapped [85] and crystal structure from E. coli solved [94] 
• Active site faces the periplasm, with a V-shaped TM2 and TM3 pair suggested to 
accept membrane-associated lipid substrates, catalytic triad: H163, H207, and 
D211 [85,94] 
• Not dependent on metal ions for activity [85,92] with broad substrate specificity, 
capable of utilising a range of lipid pyrophosphates in vitro [85] 
• Activity towards C55-PP in vitro (in detergent micelles) stimulated in the presence 
of phospholipids and diacylglycerol pyrophosphate [85] 
YbjG 
• Demonstrated activity towards C55-PP [82] 
• Topology mapped with five TM helices, N-terminus in the periplasm and C-terminus 
in the cytoplasm [79] 
• Active site suggested to face the periplasm [79] 
YeiU/LpxT 
• Demonstrated activity towards C55-PP [82] 
• Topology mapped with six TM helices, both N- and C-termini in the cytoplasm [79]
• Active site suggested to face the periplasm [79] 
• Demonstrated phosphotransferase function towards Lipid A [87] 
Note: Triple deletion of bacA, pgpB, and ybjG genes is lethal to E. coli [82]. 
It is important to note that the presence of either one of UppP, PgpB, or YbjG can sustain normal 
growth in E. coli [82], indicating that each of these three membrane phosphatases can presumably 
participate in both the de novo synthesis of C55-P and the subsequent recycling of C55-PP. Since the 
above-mentioned enzymes have their active sites predicted to face the periplasm [78,79,85,94], it is 
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therefore not surprising to observe that they can functionally complement each other. However, if  
C55-PP is dephosphorylated on the periplasmic side of the cytoplasmic membrane following the action 
of class A PBPs and monofunctional glycosyltransferase, then there must be an obligatory flipping of 
the monophosphate form of the active lipid carrier prior to the recruitment by MraY to form Lipid I.  
This hypothesis should hold true unless there is another C55-PP phosphatase (unknown and yet to be 
characterised) that can perform such a function at the cytoplasmic side of the cell membrane. It has been 
postulated that a driving force for the unidirectional transbilayer movement of lipids (by passive 
diffusion or dynamic rearrangement in the cell membrane) with the accumulation of C55-PP on one side 
of the lipid bilayer would favour its translocation towards the other side, and vice versa for the case of 
C55-P [52]. Nevertheless, the presence of a dedicated protein to transport these lipid molecules is a source 
of uncertainty, particularly given the high metabolic turnover of C55-P that is required for a variety of 
cellular activities. 
6. Conclusions 
Although the pathway for peptidoglycan biosynthesis has been studied for many decades, there is  
still a great deal to discover concerning the structure and function of many of the enzymes involved and 
the coordination of their activities. Central to the overall biosynthetic process is the metabolism of  
Lipid II at and through the cytoplasmic membrane. The nature and energetics of the Lipid II translocation 
process are still a subject of controversy [95], and despite recent advances in the field, there is still much 
to decipher. Related to this metabolism is an almost complete lack of understanding of the overall 
recycling process for undecaprenyl phosphate which is present in limiting amounts in bacterial 
membranes, yet is used in a variety of different processes in bacteria [52]. There is an interesting 
analogous situation in eukaryotic membranes whereby dolichol is used as a carrier lipid for the glycan 
precursor in the early stages of N-linked protein glycosylation [96]. The molecular basis of several steps 
involved in the synthesis and the recycling of dolichol and its derivatives is still unknown, just like the 
prokaryotic counterpart. 
Clearly there is a large number of naturally occurring secondary metabolites/antimicrobials including 
the recently discovered and heralded teixobactin [21], and whilst these compounds generally target 
different aspects of the Lipid II structure, it is interesting to speculate whether direct sequestration of 
Lipid II or a consequent derailment of membrane-associated undecaprenyl phosphate metabolism is 
actually responsible for the subsequent bactericidal events. Thus, an in-depth understanding of this 
crucial process will certainly reveal the long-sought-after biological understanding of the process and 
may also lead to novel antibacterial opportunities targeting this crucial aspect of bacterial metabolism 
which could be considered an Achilles’ heel. 
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